Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).[1][2]
Clinical data | |
---|---|
Trade names | Smyraf |
Other names | ASP015K; JNJ-54781532 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
PubChem CID |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C18H22N4O2 |
Molar mass | 326.400 g·mol−1 |
3D model (JSmol) |
|
| |
|
Peficitinib was approved for use in Japan in 2019.[3]